Transcript The Company - Biopercept

Enabling rapid and simple radiolabeling of biologicals
RadTag multimodal bioimaging
Vinnova 2012-11-01
Samuel Svensson
Peter Ström
Carl M Andersson
17-Jul-15
1
Delivered 3 amyloid PET ligands to clinical testing
Nature (2008) 456
RadTags simplify radiolabeling of biologicals
Enabling
”Agents and methods for visualising analytes ”PCT/EP2011/070172
IPR fully owned by BioPercept
• Increased flexibility and specific binding
• Stable binding – small tag size reduces interference with
target protein
• PKPD studies with labeled proteins
• Companion diagnostics
• Potential for pre-targeting
Biologicals are must have for pharma
Six out of 24 new approvals by the FDA were for biologicals in 2011
-- share will increase; typical pharma ambition calls for 30-40% of pipeline
Radiolabeling within development of biologicals is very limited
-- lack of generalised radiochemical methodology
Biosimilars market estimated at USD 4,000 million in 2017
Increasing demand for ability to monitor, visualise, perform PK studies
RadTags trigger a paradigm shift
See Statement of interest (back ups)
FlAsH technology – a fluorescence labeling technology
developed for live cell imaging
(R Tsien Nobel prize 2008)
FlAsH-based protein detection available from
RadTags bind to same consensus sequence as FlAsH
Non-invasive, clean, targeted technique
Easily constructed six-amino acid tags
The CCPGCC tag can be incorporated by standard techniques
– During peptide synthesis
– Using Polymerase chain reaction (PCR)
– Using commercially available cloning vectors from Life Technologies
Promotor
Gene
CCPGCC tag (in frame)
Expression vector
RadTags enable radiolabelling using different
isotopes at the same site, Multimodal
Precursor for 18F,
121I, 125I, 131I,
Precursor for 13C,
14C, 11C, 3H, 19F
Flourescence
Preclin summary
RadTag
• form rapid and covalent binding with CCPGCC-peptides
• can rapidly be radiolabeled with [14C] & [3H]
• bound to modifed a-MSH peptide retain pharmacological potency
S
S
S
O
S
As
As
O
F
O
RadTag Gan chart
Project Ac vity
2013
Q1
2013
Q2
2013 2013
Q3
Q4
2014
Q1
Commercial pot.
[3H]-Methyla on
Autorad
Xenograf ex vivo
microPET
Commercial: InnovationskontorEtt LiU
Technical PoC: Prof Victor Hruby
2014
Q2
2014
Q3
2014
Q4
PoC study: PET Melanoma
Ac-Nle-Asp-His-(D)Phe-Arg-Trp-Gly-Lys-Arg-Trp-Cys-Cys-Pro-Gly-Cys-Cys-Lys-Thr-Phe
Cheng et al J Nucl Med 2007; 48:987–994
PoC study: PET Melanoma
RadTag-MSH [125I]NDP-a-MSH at hMCR1
RadTag-a-MSH retain same binding profile as a-MSH
The Team
Samuel Svensson, PhD
• Professor of Pharmacology, LiU. Principal scientist
AstraZeneca R&D. Project leader PET ligand project
2004-2011 (AZD2184, 2995, 4694).
Chairman BioPercept
Peter Ström, MSc
• Radiochemist with 20+ years experience within
AstraZeneca. CSO radiochemistry BioPercept
Carl M Andersson, PhD, associate professor
• Organic chemist. Consultant with 20+ years experience
from senior managerial positions within biotech and
pharma. CEO BioPercept
Åsa Wallin Affärsutvecklare InnovationskontorEtt LiU
Financing and partners
• Innovationsbron
• Innovationskontoret, LiU, Maria Swartz
• Competence Network AB, Södertälje
• Prof Peter Konradsson, Organic Chemistry LiU
www.biopercept.com